KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Other Operating Expenses (2016 - 2025)

Sarepta Therapeutics (SRPT) has 10 years of Other Operating Expenses data on record, last reported at $306.9 million in Q4 2024.

  • For Q4 2024, Other Operating Expenses changed N/A year-over-year to $306.9 million; the TTM value through Sep 2025 reached $306.9 million, up 33.5%, while the annual FY2023 figure was $102.0 million, N/A changed from the prior year.
  • Other Operating Expenses reached $306.9 million in Q4 2024 per SRPT's latest filing, up from $229.9 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $306.9 million in Q4 2024 and bottomed at -$14.3 million in Q3 2020.
  • Average Other Operating Expenses over 5 years is $76.3 million, with a median of $34.7 million recorded in 2023.
  • The widest YoY moves for Other Operating Expenses: up 62930.81% in 2020, down 1343.97% in 2020.
  • A 5-year view of Other Operating Expenses shows it stood at -$14.3 million in 2020, then soared by 264.79% to $23.6 million in 2021, then skyrocketed by 60.76% to $38.0 million in 2022, then decreased by 9.67% to $34.3 million in 2023, then skyrocketed by 794.55% to $306.9 million in 2024.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $306.9 million in Q4 2024, $229.9 million in Q1 2024, and $34.3 million in Q2 2023.